When Huntik Season 2 Begin?

George Soros is invested in biotechnology, although it does express some of their profits


As we said recently strong hands were invested in biotechnology , an extreme example of this is George Soros.
George Soros is for many the archetype of the speculator and prophet of "post-capitalism." Is American, although born in Budapest. Today is one of the richest men in the world but has been emigrant painter and porterage. As head of various "cracks in the stock market", while patrons in about fifty countries through grants to human rights organizations, scholarships for black students in South Africa and support for various social projects in Eastern Europe , is flattered and feared at the same time. It currently has a fortune estimated at 7 billion dollars, but manages many billions more dollars in markets worldwide, and their movements Money is capable of changing the destiny of a country, a currency or an industry.
In June this year, Soros had invested in biotechnology and pharmaceutical companies 49% of their funds. An outrage to everyone, but much more for a financial speculator not particularly versed in the field. For example, in telecommunications was only slightly less than 3% and the second sector in which he invested was more consumer services (which are included supermarkets, media, leisure and travel agencies and tourism and leisure) a sector was exposed in just under 19%. But today has been known that, throughout the summer Soros had sold a large part of their biotechnological reducing their exposure to 25.2%. Biotechnology still remains the sector in which has a greater exposure, especially biotechnology and pharmaceutical companies American, recently commented that as well are our favorites, even ahead of the telecommunications, oil (7%) or consumer services, where their exposure is still below 25%.
obviously has taken a good return on their bios, because as we said before the AMEX biotech has risen sharply this year that could or . A good collection of benefits and remains heavily exposed to the sector.

When Huntik Season 2 Begin?

George Soros is invested in biotechnology, although it does express some of their profits


As we said recently strong hands were invested in biotechnology , an extreme example of this is George Soros.
George Soros is for many the archetype of the speculator and prophet of "post-capitalism." Is American, although born in Budapest. Today is one of the richest men in the world but has been emigrant painter and porterage. As head of various "cracks in the stock market", while patrons in about fifty countries through grants to human rights organizations, scholarships for black students in South Africa and support for various social projects in Eastern Europe , is flattered and feared at the same time. It currently has a fortune estimated at 7 billion dollars, but manages many billions more dollars in markets worldwide, and their movements Money is capable of changing the destiny of a country, a currency or an industry.
In June this year, Soros had invested in biotechnology and pharmaceutical companies 49% of their funds. An outrage to everyone, but much more for a financial speculator not particularly versed in the field. For example, in telecommunications was only slightly less than 3% and the second sector in which he invested was more consumer services (which are included supermarkets, media, leisure and travel agencies and tourism and leisure) a sector was exposed in just under 19%. But today has been known that, throughout the summer Soros had sold a large part of their biotechnological reducing their exposure to 25.2%. Biotechnology still remains the sector in which has a greater exposure, especially biotechnology and pharmaceutical companies American, recently commented that as well are our favorites, even ahead of the telecommunications, oil (7%) or consumer services, where their exposure is still below 25%.
obviously has taken a good return on their bios, because as we said before the AMEX biotech has risen sharply this year that could or . A good collection of benefits and remains heavily exposed to the sector.

Panera Bread Hazelnut Coffee

Picking on a boat in Venice or a guide map for Biotechs buy American.



If you've seen Casino Royale, the latest James Bond film, a number of scenes in which Bond and his girl make a romantic trip on a private boat along the canals of Venice. As one of my great passions is sailing, I wondered if he could "emulate Bond" and if anyone can walk in sailing through the canals of Venice. Well, no. Prohibited from doing so and is the typical thing that only happens in movies. For starters, because the bridges are too low to drive a boat (in the photos you can see that the mast had to dismount to push the boat in the channel), but while the mast was small enough to pass, would still be banned by the Italian government.

There are many investors who are so with biotechnology, do not invest in it because it is a difficult world to understand. The manipulation of genes, DNA, RNA, stem cells, RNA interference or gene therapy. These are complicated concepts, but rather for specialists, why bother to understand how easy it is to buy an apartment or buy shares in the electrical business that is easier to understand? Moreover, most biotechnology companies listed on foreign markets. As previously ahead, American companies account for more patents interesting, which makes it even harder to know, for their developments and progress do not appear in the English media and the information is not readily accessible, is in English.

For now, faced with the choice to put me to explain these things or take a shortcut, I decided to take a risky shortcut: dump here my portfolio and see how they do. The choice I can repeat, but this is not a recommendation to buy or sell. The intention is that it serves as a roadmap in the world of biotechnology. Go up or down according to those who read me you can assess whether deserved (and deserves) getting off a boat in the canals of Venice, it is worth investing in a biotechnology company, or if we leave the world of fantasy. This is my portfolio today:

NASDAQ 9,741 U.S. DOLLARS 0.000 NASDAQ Alnylam Pharmaceuticals Inc. 2,001 U.S. DOLLARS

NEW YORK	Celera Genomics	64	880.000 U.S. DOLLARS		11/27/2006 16:01:00
	LEXIcom GENETIC		37015.800		11/27/2006 16:04:00
NASDAQ	Incyte Genomics Inc.	0			27/11/2006 U.S. DOLLARS 16:05:00
NASDAQ	ArQule Inc.		2596.770 549 U.S. DOLLARS		11/27/2006 16:07:00
			40620.300		11/27/2006 16:07:00
NASDAQ	Exelixis Inc.		523 4550, 100 U.S. DOLLARS		11/27/2006 16:08:00

As you can I have now seen a portfolio of six shares, one listed in New York and the other five listed on the Nasdaq. But every action has a very variable in my portfolio. From actions such as Alnylam, which is worth about 40mil today dollars, up actions such as Celera, whose value is now below $ 1000. All these actions have in common that, in my opinion, have the potential to multiply its value, and therefore the value of our investment, by 10 within 5 years. What venture capitalists Americans call a potential 10x/5y , 10veces in 5 years (years). I promise to tell more about these actions and their awesome potential. But also on the risks of investing in these companies ...

Panera Bread Hazelnut Coffee

Picking on a boat in Venice or a guide map for Biotechs buy American.



If you've seen Casino Royale, the latest James Bond film, a number of scenes in which Bond and his girl make a romantic trip on a private boat along the canals of Venice. As one of my great passions is sailing, I wondered if he could "emulate Bond" and if anyone can walk in sailing through the canals of Venice. Well, no. Prohibited from doing so and is the typical thing that only happens in movies. For starters, because the bridges are too low to drive a boat (in the photos you can see that the mast had to dismount to push the boat in the channel), but while the mast was small enough to pass, would still be banned by the Italian government.

There are many investors who are so with biotechnology, do not invest in it because it is a difficult world to understand. The manipulation of genes, DNA, RNA, stem cells, RNA interference or gene therapy. These are complicated concepts, but rather for specialists, why bother to understand how easy it is to buy an apartment or buy shares in the electrical business that is easier to understand? Moreover, most biotechnology companies listed on foreign markets. As previously ahead, American companies account for more patents interesting, which makes it even harder to know, for their developments and progress do not appear in the English media and the information is not readily accessible, is in English.

For now, faced with the choice to put me to explain these things or take a shortcut, I decided to take a risky shortcut: dump here my portfolio and see how they do. The choice I can repeat, but this is not a recommendation to buy or sell. The intention is that it serves as a roadmap in the world of biotechnology. Go up or down according to those who read me you can assess whether deserved (and deserves) getting off a boat in the canals of Venice, it is worth investing in a biotechnology company, or if we leave the world of fantasy. This is my portfolio today:

NASDAQ 9,741 U.S. DOLLARS 0.000 NASDAQ Alnylam Pharmaceuticals Inc. 2,001 U.S. DOLLARS

NEW YORK	Celera Genomics	64	880.000 U.S. DOLLARS		11/27/2006 16:01:00
	LEXIcom GENETIC		37015.800		11/27/2006 16:04:00
NASDAQ	Incyte Genomics Inc.	0			27/11/2006 U.S. DOLLARS 16:05:00
NASDAQ	ArQule Inc.		2596.770 549 U.S. DOLLARS		11/27/2006 16:07:00
			40620.300		11/27/2006 16:07:00
NASDAQ	Exelixis Inc.		523 4550, 100 U.S. DOLLARS		11/27/2006 16:08:00

As you can I have now seen a portfolio of six shares, one listed in New York and the other five listed on the Nasdaq. But every action has a very variable in my portfolio. From actions such as Alnylam, which is worth about 40mil today dollars, up actions such as Celera, whose value is now below $ 1000. All these actions have in common that, in my opinion, have the potential to multiply its value, and therefore the value of our investment, by 10 within 5 years. What venture capitalists Americans call a potential 10x/5y , 10veces in 5 years (years). I promise to tell more about these actions and their awesome potential. But also on the risks of investing in these companies ...

Checkered Metal Cores

strong hands are always ahead: The wealthy take positions in biotechnology.

All
economic growth cycle has stages. If the industry is not new, as with biotechnology, usually comes from a long trek through the desert where nobody wants or hear about investing in it. In the case of changes, come from the phase of euphoria in 2000, when the announcement of the human genome sequence shot contributions biotechnology companies worldwide. In Spain we had our particular local mini-episode Zeltia. That turned into a bubble, with stratospheric valuations for an industry which still had many years to be really competitive. Experts begin selling and went into a tragic phase. Many lost a lot of money around the world. Biotechnology lost interest. In Spain, many were left with Zeltia and / or Puleva Biotech worth 30% to 60% less than it was worth. And years went by without recovery. The people, the weak hands, swore never to invest in bios. But things are changing. The reasons why those companies achieved huge market prices remain, some have already commented in the previous post: The boom in the elderly: an investment opportunity?

In these seven years, industry has also matured and business prospects are improving. The first sign of this change in perception is that strong hands are taking positions, the great fortunes begin to see the sector differently. For example, BBVA wealth manager, a unit aimed at customers with more than two billion euros of assets, said in an interview that they are already preparing to take positions biotechnology . Strong hands are always ahead.

The second sign of change, is that prices start to rise. The Amex biotech index has risen this year, so far, 15.3%, four percentage points higher than the S & P500. Some companies, like those who work in RNA interference technology, technology that has won the Nobel Prize for Medicine this year have risen by 321%, and Sirna Therapeutics and Alnylam Pharmaceuticals, more than 50%. Yet this increase is hardly noticed. Still have not even caught our biotechnological Zeltia, for example, loses this year, more than three percentage points, and that in a great year for stocks. This can mean two things: one, that the English business cycle is delayed by about 9 months with the U.S. cycle and the infection will come next year. Two, that the English biotechnology has lost the car of progress and that no Biotechs can be invested in Spain because the companies that have garnered the most valuable patents are in the United States. My opinion? There is something of both, but that we'll talk later, if no chance ...

Checkered Metal Cores

strong hands are always ahead: The wealthy take positions in biotechnology.

All
economic growth cycle has stages. If the industry is not new, as with biotechnology, usually comes from a long trek through the desert where nobody wants or hear about investing in it. In the case of changes, come from the phase of euphoria in 2000, when the announcement of the human genome sequence shot contributions biotechnology companies worldwide. In Spain we had our particular local mini-episode Zeltia. That turned into a bubble, with stratospheric valuations for an industry which still had many years to be really competitive. Experts begin selling and went into a tragic phase. Many lost a lot of money around the world. Biotechnology lost interest. In Spain, many were left with Zeltia and / or Puleva Biotech worth 30% to 60% less than it was worth. And years went by without recovery. The people, the weak hands, swore never to invest in bios. But things are changing. The reasons why those companies achieved huge market prices remain, some have already commented in the previous post: The boom in the elderly: an investment opportunity?

In these seven years, industry has also matured and business prospects are improving. The first sign of this change in perception is that strong hands are taking positions, the great fortunes begin to see the sector differently. For example, BBVA wealth manager, a unit aimed at customers with more than two billion euros of assets, said in an interview that they are already preparing to take positions biotechnology . Strong hands are always ahead.

The second sign of change, is that prices start to rise. The Amex biotech index has risen this year, so far, 15.3%, four percentage points higher than the S & P500. Some companies, like those who work in RNA interference technology, technology that has won the Nobel Prize for Medicine this year have risen by 321%, and Sirna Therapeutics and Alnylam Pharmaceuticals, more than 50%. Yet this increase is hardly noticed. Still have not even caught our biotechnological Zeltia, for example, loses this year, more than three percentage points, and that in a great year for stocks. This can mean two things: one, that the English business cycle is delayed by about 9 months with the U.S. cycle and the infection will come next year. Two, that the English biotechnology has lost the car of progress and that no Biotechs can be invested in Spain because the companies that have garnered the most valuable patents are in the United States. My opinion? There is something of both, but that we'll talk later, if no chance ...

Back Waxing Mississauga

The boom in the elderly: an investment opportunity?

aging Talking is not the most educated to start a blog, but the fact that the world population ages. From current trends continue, within 50 years with 2,000 million seniors worldwide and 22% of the world's population will be over 60 years. Today, the number of seniors already exceeds the children in developed regions, and each month, one million people reach age 60. 'And contrary to popular belief this is not a phenomenon unique to Europe and the U.S.. In fact, developing countries will experience the aging process more meaningful. By 2025, the old people in Colombia, Indonesia and Kenya will increase eight times more than in European countries traditionally "old." How can an investor take advantage of this global trend? If young and middle-aged people have spent at leisure and housing, encouraging housing growth and leisure activities associated with the generation of "Baby Boom", what that older people spend their money? How do the elderly spend the Baby Boom generation of money? Statistics say that in medicine.
is known that the elderly spend more on health care than any other thing in their lives. For example, over 75 represent 30% of health spending, but only 5% of the population. And more and more elderly pay for their treatment in private clinics, a growing trend.

But this is just one of the legs which holds an unprecedented investment opportunity. If this increasing demand meets supply increased, opportunities for investment in biotechnology can be great. And that is precisely the scenario that awaits us in the coming years. After sequencing the human genome, knowledge of genetic circuits that regulate aging and the cause of diseases like cancer or diabetes is exploding. Some scientists are starting to say that aging "is not biologically inevitable" :

recently been discovered that aging is genetically controlled. And maybe death is genetically controlled. And something that is genetically controlled is or will be manipulated. The genetic program of aging is highly variable depending on the species. There are turtles living hundreds of years and trees that live thousands of years. But if we assume that aging genes can be manipulated, because in theory, why not: we aspire to immortality. It would be manipulated to our benefit the genes that control aging. In fact there is some part of us that it is immortal and is perpetuated in our children. And cancer cells are transformed, they seem to be immortal. All these possibilities are remote and have a background of speculation. But there is speculation.

If humanity is moving towards immortality, who would not pay for living longer and better, drugs have increasingly efficient? Get Ready for the next boom after the leisure and housing market, the boom of treating an aging population but almost starts to buy his immortality with money. Is it time to start investing in biotechnology?

Back Waxing Mississauga

The boom in the elderly: an investment opportunity?

aging Talking is not the most educated to start a blog, but the fact that the world population ages. From current trends continue, within 50 years with 2,000 million seniors worldwide and 22% of the world's population will be over 60 years. Today, the number of seniors already exceeds the children in developed regions, and each month, one million people reach age 60. 'And contrary to popular belief this is not a phenomenon unique to Europe and the U.S.. In fact, developing countries will experience the aging process more meaningful. By 2025, the old people in Colombia, Indonesia and Kenya will increase eight times more than in European countries traditionally "old." How can an investor take advantage of this global trend? If young and middle-aged people have spent at leisure and housing, encouraging housing growth and leisure activities associated with the generation of "Baby Boom", what that older people spend their money? How do the elderly spend the Baby Boom generation of money? Statistics say that in medicine.
is known that the elderly spend more on health care than any other thing in their lives. For example, over 75 represent 30% of health spending, but only 5% of the population. And more and more elderly pay for their treatment in private clinics, a growing trend.

But this is just one of the legs which holds an unprecedented investment opportunity. If this increasing demand meets supply increased, opportunities for investment in biotechnology can be great. And that is precisely the scenario that awaits us in the coming years. After sequencing the human genome, knowledge of genetic circuits that regulate aging and the cause of diseases like cancer or diabetes is exploding. Some scientists are starting to say that aging "is not biologically inevitable" :

recently been discovered that aging is genetically controlled. And maybe death is genetically controlled. And something that is genetically controlled is or will be manipulated. The genetic program of aging is highly variable depending on the species. There are turtles living hundreds of years and trees that live thousands of years. But if we assume that aging genes can be manipulated, because in theory, why not: we aspire to immortality. It would be manipulated to our benefit the genes that control aging. In fact there is some part of us that it is immortal and is perpetuated in our children. And cancer cells are transformed, they seem to be immortal. All these possibilities are remote and have a background of speculation. But there is speculation.

If humanity is moving towards immortality, who would not pay for living longer and better, drugs have increasingly efficient? Get Ready for the next boom after the leisure and housing market, the boom of treating an aging population but almost starts to buy his immortality with money. Is it time to start investing in biotechnology?